Abrilumab

Drug Profile

Abrilumab

Alternative Names: Abrilimumab; AMG-181; Anti-α4β7 integrin monoclonal antibody; MEDI-7183

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 28 Jul 2015 Phase-II development in Crohn's disease and Ulcerative colitis is ongoing worldwide
  • 19 Jun 2015 Amgen completes enrolment in its phase II trial for Crohn's disease in USA, Canada, European Union and Switzerland (NCT01696396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top